Testing effectiveness (Phase 2)Study completedNCT03560531What this trial is testingZN-c5 in Subjects With Breast CancerWho this might be right forBreast Cancer Zeno Alpha Inc. 181
Testing effectiveness (Phase 2)UnknownNCT05044988What this trial is testingHS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast CancerWho this might be right forHR+/HER2- Advanced and/or Metastatic Breast Cancer Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Not applicableLooking for participantsNCT06781281What this trial is testingNabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.Who this might be right forBreast Cancer Invasive Henan Cancer Hospital 709
Testing effectiveness (Phase 2)Active Not RecruitingNCT04553133What this trial is testingPF-07104091 as a Single Agent and in Combination TherapyWho this might be right forSmall Cell Lung CancerOvarian CancerBreast Cancer Pfizer 157
Testing effectiveness (Phase 2)Study completedNCT03280563What this trial is testingMultiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerWho this might be right forBreast Neoplasms Hoffmann-La Roche 144
Not applicableEnded earlyNCT04967248What this trial is testingA NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world SettingWho this might be right forHormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation Novartis Pharmaceuticals 4
Testing effectiveness (Phase 2)Study completedNCT06465368What this trial is testingLearn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post MenopauseWho this might be right forBreast Cancer Pfizer 121
Large-scale testing (Phase 3)Looking for participantsNCT07071337What this trial is testingSKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine TherapyWho this might be right forMetastatic Breast Cancer Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 430
Large-scale testing (Phase 3)Study completedNCT05375461What this trial is testingTQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical TrailWho this might be right forHR-positive,HER2-negative in Advanced Breast Cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 293
Early research (Phase 1)Active Not RecruitingNCT06299124What this trial is testingA Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid TumorsWho this might be right forBreast CancerAdvanced Solid Tumor Regor Pharmaceuticals Inc. 40
Early research (Phase 1)WithdrawnNCT05905341What this trial is testingStudy of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.Who this might be right forBreast CancerOvarian CancerLiposarcoma+3 more Pfizer
Not applicableStudy completedNCT03583463What this trial is testingALEXANDRIA Study EgyptWho this might be right forBreast Cancer AstraZeneca 436
Not applicableStudy completedNCT05153187What this trial is testingReal-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in JapanWho this might be right forBreast Cancer Pfizer 1,170
Not applicableStudy completedNCT04736576What this trial is testingStudy to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine MonotherapyWho this might be right forBreast Cancer Pfizer 99
Testing effectiveness (Phase 2)UnknownNCT04318223What this trial is testingPalbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal TherapyWho this might be right forMetastatic Breast CancerLocally Advanced Breast Cancer Consorzio Oncotech 168
Not applicableNot Yet RecruitingNCT07701070What this trial is testingSHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBCWho this might be right forAdvanced Breast Cancer AstraZeneca 3,000
Not applicableStudy completedNCT05132101What this trial is testingAnalysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South KoreaWho this might be right forMetastatic Breast Cancer Pfizer 2,758
Testing effectiveness (Phase 2)Ended earlyNCT00759642What this trial is testingLapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone TherapyWho this might be right forMetastatic Breast Cancer University of Kansas Medical Center 33
Testing effectiveness (Phase 2)Study completedNCT05963984What this trial is testingSamuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult ParticipantsWho this might be right forMetastatic Breast CancerLocally Advanced Breast CancerBreast Cancer Carrick Therapeutics Limited 60
Testing effectiveness (Phase 2)Looking for participantsNCT05735080What this trial is testingOpen-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerWho this might be right forBreast CancerBreast Cancer MetastaticHormone Receptor Positive Tumor+6 more Incyclix Bio 150